The clinical spectrum of levodopa-induced motor complications

Journal of Neurology

Volumn 257, Issue SUPPL. 2, 2010, Pages

  Hametner, E ^a   Seppi, K ^a   Poewe, W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

LD induced dyskinesias; Levodopa; Motor fluctuations; Motor response oscillations; Parkinson's disease; Pulsatile stimulation

Indexed keywords

DOPAMINE RECEPTOR; LEVODOPA; ANTIPARKINSON AGENT;

CONFERENCE PAPER; DISABILITY; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; OSCILLATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; REVIEW;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 80052550011     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5719-9     Document Type: Conference Paper

References (68)

1. Alexander G, Crutcher M (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13:266-271 (Pubitemid 20193456)
2. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20:224-230 (Pubitemid 40361128)
3. Clarke C, Davies P (2000) Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 69:590-594
4. Colosimo C, Martínez-Martín P, Fabbrini G, Hauser R, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins G, Schrag A, Goetz C (2010) Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord 25:1131-1142
5. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1999) Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuation in Parkinson's disease. Clin Neuropharmacol 22:351-355
6. Damiano A, McGrath M, Willian M, Snyder C, LeWitt P, Reyes P, Richter R, Means E (2000) Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 9:87-100 (Pubitemid 30670652)
7. De Rijk M, Launer L, Berger K, Breteler M, Dartigues J, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(Suppl 5):21-23
8. Djaldetti R, Baron J, Ziv I, Melamed E (1996) Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 46:1051-1054 (Pubitemid 26134650)
9. Djaldetti R, Inzelberg R, Giladi N, Korczyn A, Peretz-Aharon Y, Rabey M, Herishano Y, Honigman S, Badarny S, Melamed E (2002) Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 17:297-302 (Pubitemid 36041298)
10. Dodel R, Berger K, Oertel W (2001) Health-related quality of life and healthcare utilisation in patients with Parkinson's disease. Pharmacoeconomics 19:1013-1038 (Pubitemid 33701931)
11. Encarnacion E, Hauser R (2008) Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 60:57-66
12. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow C, Tanner C, Marek K, Group PS (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
13. Forno L (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272
14. Gerfen C, Engber T, Mahan L et al (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432 (Pubitemid 120031867)
15. Goetz C (1999) Rating scales for dyskinesias in Parkinson's disease. Mov Disord 14(Suppl 1):48-53
16. Goetz C, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020-1028 (Pubitemid 39302834)
17. PS Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23:34-44
18. Hauser R, Friedlander J, Zesiewicz T, Adler C, Seeberger L, O'Brien C, Molho E, Factor S (2000) A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 23:75-81 (Pubitemid 30212216)
19. Hauser R, McDermott M, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63:1756-1760 (Pubitemid 44925085)
20. Herrero M, Augood S, Hirsch E et al (1995) Effects of L-dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68:1189-1198
21. Hoehn M (1992) The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 10:311-339
22. Holloway R, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell D, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Group PS (2004) Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044-1053 (Pubitemid 38915945)
23. http://www.clinicaltrial.gov/ct2/show/NCT01071395 (2010) Validation of dyskinesia rating scales. In: clinicaltrials.gov (ed)
24. Hung S, Adeli G, Arenovich T, Fox S, Lang A (2007) Patient perception of dyskinesias in Parkinson's disease. Neurology 68:A232
25. Jolkkonen J, Jenner P, Marsden C (1995) L-Dopa reverses altered gene expression of substance P but not enkephalin in the caudateputamen of common marmosets treated with MPTP. Brain Res Mol Brain Res 32:297-307
26. Jost W (2010) Gastrointestinal dysfunction in Parkinson's disease. J Neurol Sci 289:69-73
27. Karlsen K, Tandberg E, Arsland D, Larsen J (2000) Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 69:584-589
28. Kish S, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880 (Pubitemid 18090271)
29. Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41:202-205
30. Krygowska-Wajs A, Lorens K, Thor P, Szczudlik A, Konturek S (2000) Gastric electromechanical dysfunction in Parkinson's disease. Funct Neurol 15:41-46 (Pubitemid 30255369)
31. Künzle H (1975) Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis. Brain Res 88:195-209
32. Leenders K, Poewe W, Palmer A, Brenton D, Frackowiak R (1986) Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258-262 (Pubitemid 16044213)
33. Lees A (1987) A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. Eur Neurol 27:126-134
34. Lees A, Katzenschlager R, head J, Ben-Shlomo Y (2001) Ten year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57:1687-1694 (Pubitemid 33055490)
35. Luquin M, Scipioni O, Vaamonde J, Gershanik O, Obeso J (1992) Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 7:117-124
36. Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 9:2-12 (Pubitemid 24022609)
37. Marsden C (1994) Parkinson's disease. J Neurol Neurosurg Psychiatry 57:672-681
38. Melamed E (1979) Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 36:308-310
39. Muenter M, Sharpless N, Tyce G, Darley F (1977) Patterns of dystonia ("I-D-I" and "D-I-D-") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 52:163-174
40. Nutt J (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340-345
41. Nutt J, Fellman J (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35-49 (Pubitemid 14138567)
42. Nutt J, Woodward W (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating Parkinsonian patients. Neurology 36:739-744 (Pubitemid 16056209)
43. Nutt J, Wooten G (2005) Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 353:1021-1027 (Pubitemid 41262336)
44. Oertel W, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset D, Arnold G, Leenders K, Hundemer H, Lledó A, Wood A, Frewer P, Schwarz J (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET Study. Mov Disord 21:343-353
45. Olanow C, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston W, LeWitt P, Melamed E, Mena M, Michel P, Mytilineou C, Obeso J, Poewe W, Quinn N, Raisman-Vozari R, Rajput A, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19:997-1005 (Pubitemid 39302831)
46. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G (1995) "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 10:333-336
47. Paci C, Thomas A, Onofrj M (2001) Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 22:75-76 (Pubitemid 32622275)
48. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A (2006) Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology 66:1824-1829 (Pubitemid 44049810)
49. Poewe W, Lees A, Stern G (1988) Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 23:73-78
50. Poewe W, Lees A, Stern G (1986) Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36:1528-1530 (Pubitemid 17175783)
51. Quinn N, Critchley P, Marsden C (1987) Young onset Parkinson's disease. Mov Disord 2:73-91
52. Rajput A (1992) Frequency and cause of Parkinson's disease. Can J Neurol Sci 19(Suppl 1):103-107
53. Rajput A (2001) Levodopa prolongs life expectancy and is nontoxic to substantia nigra. Parkinsonism Relat Disord 8:95-100
54. Rascol O, Brooks D, Korczyn A, De Deyne P, Clarke C, Lang A (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491 (Pubitemid 30318272)
55. Rascol O, Brooks D, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, group Ls (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallelgroup trial. Lancet 365:947-954 Mar 12-18
56. Rinne U, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso J, Montastruc J, Marsden C (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):23-30
57. Schrag A, Ben-Shlomo Y, Brown R, Marsden C, Quinn N (1998) Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 13:885-894 (Pubitemid 28517664)
58. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123(Pt 11):2297-2305
59. Snow B, Macdonald L, Mcauley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23:82-85 (Pubitemid 30212217)
60. Soykan I, Lin Z, Bennett J, McCallum R (1999) Gastric myoelectrical activity in patients with Parkinson's disease: evidence of a primary gastric abnormality. Dig Dis Sci 44:927-931 (Pubitemid 29205602)
61. Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen J, LeWitt P, Oertel W, Quinn N, Sethi K, Stocchi F (2005) Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20:726-733 (Pubitemid 41051784)
62. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang A, Olanow C (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18-27
63. Tanner C, Goldman S (1996) Epidemiology of Parkinson's disease. Neurol Clin 14:317-335 (Pubitemid 26157425)
64. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian M, Chase T (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326 (Pubitemid 28240346)
65. Whone A, Watts R, Stoessl A, Davis M, Reske S, Nahmias C, Lang A, Rascol O, Ribeiro M, Remy P, Poewe W, Hauser R, Brooks D, Group R-PS (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET Study. Ann Neurol 54:93-101 (Pubitemid 36764985)
66. Witjas T, Kaphan E, Azulay J, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif A (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59:408-413 (Pubitemid 34857934)
67. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 25(10):1357-1363
68. Zeng B, Pearce R, MacKenzie G, Jenner P (2000) Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-dopa. Eur J Neurosci 12:1096-1104 (Pubitemid 30168788)